WWOX, the tumour suppressor gene affected in multiple cancers

Journal of Physiology and Pharmacology

Volumn 60, Issue SUPPL. 1, 2009, Pages 47-56

  Lewandowska, U ^a   Zelazowski, M ^a   Seta, K ^a   Byczewska, M ^a   Pluciennik, E ^a   Bednarek, A K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; CpG islands; DNA methylation; Gene expression regulation; Real time polymerase chain reaction; Tumour suppressor

Indexed keywords

ALLELE; BREAST CANCER; CARCINOGENESIS; CELLULAR DISTRIBUTION; CHROMOSOME 16Q; CONFERENCE PAPER; DNA METHYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE LOCATION; HUMAN; MULTIPLE CANCER; NONHUMAN; OVARY CANCER; PHENOTYPE; PROGNOSIS; PROSTATE CANCER; TUMOR SUPPRESSOR GENE; WWOX GENE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; OXIDOREDUCTASES; TUMOR SUPPRESSOR PROTEINS;

EID: 67749116085     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 1996; 56: 5605-5609. (Pubitemid 26422160)
2. Paige AJ, Taylor KJ, Stewart A et al. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 2000; 60: 1690-1697. (Pubitemid 30183443)
3. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WWdomain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000; 60: 2140-2145. (Pubitemid 30225175)
4. Ludes-Meyers JH, Bednarek AK, Popescu NC, Bedford M, Aldaz CM. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 2003; 100: 101-110. (Pubitemid 37467796)
5. Aqeilan RI, Pekarsky Y, Herrero JJ et al. Functional association between WWOX tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA 2004; 101: 4401-4406. (Pubitemid 38437424)
6. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res 2004; 64: 8256-8261. (Pubitemid 39491763)
7. Aqeilan RI, Donati V, Palamarchuk A et al. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 2005; 65: 6764-6772. (Pubitemid 41060714)
8. Aqeilan RI, Donati V, Gaudio E et al. Association of Wwox with ErbB4 in breast cancer. Cancer Res 2007; 67: 9330-9336. (Pubitemid 47535922)
9. Bednarek AK, Keck-Waggoner CL, Daniel RL et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001; 61: 8068-8073. (Pubitemid 33091591)
10. Chang NS, Pratt N, Heath J et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 2001; 276: 3361-3370. (Pubitemid 37411633)
11. Strous GJ, van Kerkhof P, van Meer G, Rijnboutt S, Stoorvogel W. Differential effects of brefeldin Aon transport of secretory and lysosomal proteins. J Biol Chem 1993; 268: 2341-2347. (Pubitemid 23057849)
12. Paige AJ, Taylor KJ, Taylor C et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 2001; 98: 11417-11422. (Pubitemid 32928743)
13. Kuroki T, Trapasso F, Shiraishi T et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 2002; 62: 2258-2260. (Pubitemid 34411701)
14. Yendamuri S, Kuroki T, Trapasso F et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 2003; 63: 878-881. (Pubitemid 36231991)
15. Ishii H, Furukawa Y. Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol 2004; 79: 238-242. (Pubitemid 38620772)
16. Kuroki T, Yendamuri S, Trapasso F et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 2004; 10: 2459-2465. (Pubitemid 38445707)
17. Aqeilan RI, Kuroki T, Pekarsky Y et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 2004; 10: 3053-3058. (Pubitemid 38619682)
18. Park SW, Ludes-Meyers J, Zimonjic DB, Durkin ME, Popescu NC, Aldaz CM. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 2004; 91: 753-759. (Pubitemid 39141636)
19. Nunez MI, Ludes-Meyers J, Abba MC et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 2005; 89: 99-105. (Pubitemid 40249042)
20. Nunez MI, Rosen DG, Ludes-Meyers JH et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 2005; 5: 64.
21. Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX-the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol 2006; 32: 153-157. (Pubitemid 43257115)
22. Qin HR, Iliopoulos D, Semba S et al. A role for the WWOX gene in prostate cancer. Cancer Res 2006; 66: 6477-6481. (Pubitemid 44085599)
23. Donati V, Fontanini G, Dell'Omodarme M et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res 2007; 13: 884-891. (Pubitemid 46340363)
24. Aqeilan RI, Hagan JP, Aqeilan HA, Pichiorri F, Fong LY, Croce CM. Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res 2007; 67: 5606-5610. (Pubitemid 46984989)
25. Jenner MW, Leone PE, Walker BA et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007; 110: 3291-3300.
26. Dias EP, Pimenta FJ, Sarquis MS et al. Association between decreased WWOX protein expression and thyroid cancer development. Thyroid 2007; 17: 1055-1059.
27. Pimenta FJ, Cordeiro GT, Pimenta LG et al. Molecular alterations in the tumor suppressor gene WWOX in oral leukoplakias. Oral Oncol 2008; 44: 753-758.
28. Aarhus M, Bruland O, Bredholt G et al. Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas. J Neurooncol 2008; 88: 251-259.
29. Ramos D, Abba M, Lopez-Guerrero JA et al. Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours. Histopathology 2008; 52: 831-839. (Pubitemid 351724906)
30. Alsop AE, Taylor K, Zhang J, Gabra H, Paige AJ, Edwards PA. Homozygous deletions may be markers of nearby heterozygous mutations: The complex deletion at FRA16D in the HCT116 colon cancer cell line removes exons of WWOX. Genes Chromosomes Cancer 2008; 47: 437-447.
31. Finnis M, Dayan S, Hobson L et al. Common chromosomal fragile site FRA16D mutation in cancer cells. Hum Mol Genet 2005; 14: 1341-1349. (Pubitemid 40744492)
32. Ried K, Finnis M, Hobson L et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 2000; 9: 1651-1663. (Pubitemid 30427002)
33. Iliopoulos D, Guler G, Han SY et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005; 24: 1625-1633. (Pubitemid 40396092)
34. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Muller SC, von Rucker A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007; 51: 665-674. (Pubitemid 46097267)
35. Gourley C, Paige AJ, Taylor KJ et al. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol 2005; 26: 1681-1689.
36. Ludes-Meyers JH, Kil H, Bednarek AK, Drake J, Bedford MT, Aldaz CM. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene 2004; 23: 5049-5055. (Pubitemid 38938738)
37. Matsuda A, Suzuki Y, Honda G et al. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 2003; 22: 3307-3318. (Pubitemid 36712943)
38. Winfield SL, Tayebi N, Martin BM, Ginns EI, Sidransky E. Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res 1997; 7: 1020-1026. (Pubitemid 27487766)
39. Moriwaki Y, Begum NA, Kobayashi M, Matsumoto M, Toyoshima K, Seya T. Mycobacterium bovis Bacillus Calmette-Guerin and its cell wall complex induce a novel lysosomal membrane protein, SIMPLE, that bridges the missing link between lipopolysaccharide and p53-inducible gene, LITAF(PIG7), and estrogen-inducible gene, EET-1. J Biol Chem 2001; 276: 23065-23076. (Pubitemid 37411000)
40. Chen HI, Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA 1995; 92: 7819-7823.
41. Kay BK, Williamson MP, Sudol M. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J 2000; 14: 231-241. (Pubitemid 30086060)
42. Sudol M, Hunter T. NeW wrinkles for an old domain. Cell 2000; 103: 1001-1004.
43. Kasanov J, Pirozzi G, Uveges AJ, Kay BK. Characterizing Class I WW domains defines key specificity determinants and generates mutant domains with novel specificities. Chem Biol 2001; 8: 231-241. (Pubitemid 32296113)
44. Otte L, Wiedemann U, Schlegel B et al. WW domain sequence activity relationships identified using ligand recognition propensities of 42 WW domains. Protein Sci 2003; 12: 491-500. (Pubitemid 36241107)
45. Chang NS, Doherty J, Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem 2003; 278: 9195-9202. (Pubitemid 36800401)
46. Britto R, Umesh S, Hegde AS et al. Shift in AP-2alpha localization characterizes astrocytoma progression. Cancer Biol Ther 2007; 6: 413-418. (Pubitemid 47328310)
47. Berger AJ, Davis DW, Tellez C et al. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005; 65: 11185-11192. (Pubitemid 41713390)
48. Pellikainen J, Naukkarinen A, Ropponen K et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 2004; 40: 1485-1495. (Pubitemid 38757735)
49. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. WWOX and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res 2007; 13: 6115-6121. (Pubitemid 350075070)
50. Sudol M, Bork P, Einbond A et al. Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem 1995; 270: 14733-14741.
51. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278: 33334-33341. (Pubitemid 37055785)
52. Omerovic J, Puggioni EM, Napoletano S et al. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 2004; 294: 469-479. (Pubitemid 38326745)
53. Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY, Huebner K. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of WWOX expression. Clin Cancer Res 2007; 13: 268-274. (Pubitemid 46121879)
54. Aqeilan RI, Trapasso F, Hussain S et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 2007; 104: 3949-3954. (Pubitemid 47181559)
55. Aqeilan RI, Hassan MQ, de Bruin A et al. The WWOX tumor suppressor is essential for post-natal survival and normal bone metabolism. J Biol Chem 2008; 283: 21629-21639.
56. Lian JB, Javed A, Zaidi SK et al. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 2004; 14: 1-41. (Pubitemid 38581526)
57. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18: 2551-2562. (Pubitemid 29213286)